A rapid­ly grow­ing out­break of Ebo­la in Africa has prompt­ed a race to de­vel­op new vac­cines against the virus, even as a cru­cial or­ga­ni­za­tion spear­head­ing...

Io­n­is Phar­ma­ceu­ti­cals got FDA ap­proval of its rare neu­rode­gen­er­a­tive dis­ease treat­ment zil­gan­ersen, paving the way for the com­pa­ny’s first whol­ly owned neu­rol­o­gy prod­uct.

Ion­is'...